The Anti-Tumoral Potential of Phosphonate Analog of Sulforaphane in Zebrafish Xenograft Model

Isothiocyanates (ITCs) show strong activity against numerous human tumors. Five structurally diverse ITCs were tested in vivo using the zebrafish embryos 6 and 48 h post-fertilization (hpf). The survival rate, hatching time, and gross morphological changes were assessed 24, 48, and 72 h after treatment with all compounds in various doses (1-10 mu M). As a result, we selected a phosphonate analog of sulforaphane (P-ITC; 1-3 mu M) as a non-toxic treatment for zebrafish embryos, both 6 and 48 hpf. Furthermore, the in vivo anti-cancerogenic studies with selected 3 mu M P-ITC were performed using a set of cell lines derived from the brain (U87), cervical (HeLa), and breast (MDA-MB-231) tumors. For the experiment, cells were labeled using red fluorescence dye Dil (1,1 & PRIME;-Dioctadecyl-3,3,3 & PRIME;,3 & PRIME;-Tetramethylindocarbocyanine, 10 mu g/mL) and injected into the hindbrain ventricle, yolk sac region and Cuvier duct of zebrafish embryos. The tumor size measurement after 48 h of treatment demonstrated the significant inhibition of cancer cell growth in all tested cases by P-ITC compared to the non-treated controls. Our studies provided evidence for P-ITC anti-cancerogenic properties with versatile activity against different cancer types. Additionally, P-ITC demonstrated the safety of use in the living organism at various stages of embryogenesis.

Automated summary

The study found that the phosphonate analog P-ITC can be used as a non-toxic treatment for zebrafish embryos and also shows anti-cancerogenic effects on various human tumor cell lines. Experimental results demonstrate that P-ITC significantly inhibits cancer cell growth, displaying versatile activity.